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Abstract.  The cation-independent mannose-6- 
phosphate (Man-6-P) receptor is involved in the target- 
ing of newly synthesized lysosomal hydrolases.  To in- 
vestigate the intracellular distribution of this receptor, 
a conjugate of lactoperoxidase coupled to asialooroso- 
mucoid was used to catalyze its iodination within the 
endosomes of human hepatoma (HepG2) cells. The 
215-kD,  cation-independent Man-6-P receptor was io- 
dinated by this procedure as shown by pentamannosyl- 
6-phosphate-Sepharose affinity chromatography and by 
immunoprecipitation  of labeled cell extracts.  The 
amount of this receptor detected in endosomes was 
found to be unchanged after inhibition of protein 
synthesis with cycloheximide. If the Man-6-P receptor 
accumulates in the Golgi apparatus  in the absence of 
lysosomal hydrolase synthesis,  it should have been 
correspondingly depleted from endosomes after a 
period of cycloheximide treatment,  because these 
pools of receptor are in rapid equilibrium.  Therefore, 
these data suggest that newly synthesized ligands are 
not required for the transport of the cation-inde- 
pendent Man-6-P receptor from the Golgi apparatus to 
endosomes. 
p 
ROTEINS destined for the plasma membrane, secretory 
vesicles,  and lysosomes traverse a common pathway 
of intracellular  transport until they reach the Golgi ap- 
paratus, where they are somehow sorted to their correct des- 
tinations.  The targetting of proteins to lysosomes is presently 
understood in the greatest detail (see 20, 30, 37 for review). 
Upon arrival in the Golgi apparatus,  newly synthesized lyso- 
somal hydrolases are recognized by an N-acetylglucosaminyl 
phosphotransferase  (16, 28)  which  adds  N-acetylglucos- 
amine phosphate to terminal  ¢t-1,2 mannose residues (7). 
A specific phosphodiesterase (35, 38) then removes the Glc- 
NAc to generate the mannose-6-phosphate  (Man-6-P) 1 resi- 
dues that  enable lysosomal enzymes to bind to Man-6-P 
receptors in the Golgi apparatus  (20, 30, 37). It is likely that 
receptor-bound hydrolases are then transported  to an acidic 
prelysosomal compartment,  within  which the ligand  is re- 
leased for transport to lysosomes, and the free receptor recy- 
cles back to the Golgi apparatus  (20, 30). 
Two types of Man-6-P receptors have been identified. One 
has been purified from a number of sources, and is a single 
polypeptide of 215,000 daltons (31, 34). However, the 215-kD 
receptor is not present in several cultured cell lines that ade- 
quately target their hydrolases to lysosomes (11). These cells 
enabled the discovery of a  second Man-6-P receptor (17) 
which appears to be a glycoprotein composed of three 46-kD 
subunits  (18). This receptor requires divalent  cations,  and 
has thus been termed Man-6-P receptor "CD" (cation depen- 
dent) to distinguish  it from the 215-kD cation-independent, 
Man-6-P receptor "CF' (17). 
1. Abbreviations  used in this paper: ASOR,  asialoorosomucoid;  LPO, lac- 
toperoxidase;  Man-6-P,  mannose-6-phosphate. 
At steady state, the Man-6-P receptor  c~ is located in the 
Golgi apparatus  and in endosomes; a small fraction is pres- 
ent on the cell surface (3, 14, 41). Recent experiments suggest 
that  the  Man-6-P  receptor  cI equilibrates  rapidly  between 
these compartments,  because at least 90%  of the 215-kD 
Man-6-P receptors contact extracellularly  administered  re- 
ceptor antibodies  within 90 min (29, 36).  However, several 
reports have indicated  that the receptor may accumulate in 
the cis Golgi under conditions in which synthesis of lysosom- 
al hydrolases or the Man-6-P recognition  marker is blocked 
(2, 4). These findings could only be explained if the Man-6-P 
receptor  c~  was  selectively retained  in  the  Golgi  complex 
and only exported after ligand binding. 
To study the intracellular  transport of the Man-6-P recep- 
tor  c~, we have employed an endosome-specific radiolabel- 
ing procedure to detect biochemically the 215-kD Man-6-P 
receptor when it is present in endosomes. To our surprise, 
we found that the steady-state concentration  of the Man-6-P 
receptor  c~ in endosomes of HepG2 cells was quantitatively 
unaltered  under  conditions  in  which lysosomal hydrolase 
synthesis was completely blocked. Thus,  it appears that the 
215-kD Man-6-P receptor cycles constitutively  between in- 
tracellular  compartments,  independent  of the presence of 
newly synthesized  ligands. 
Materials and Methods 
Materials 
Chemicals were from Sigma Chemical Co.  (St. Louis, MO) unless other- 
wise specified.  NaU5I and [35S]methionine were  from Amersham Corp. 
(Arlington Heights,  IL). Phosphomannan from Hansenula  holstii  (NRRL 
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out after incubating cells at 4°C for 90 min with (a)  18  gg/ml 
ASOR-LPO, (b) no ASOR-LPO, (c) 18 Ixg/ml ASOR-LPO plus 600 
Ixg/ml ASOR,  or (d)  18  gg/ml  ASOR-LPO  followed by a  5  mM 
EDTA wash at the end of the pretreatment period.  The sample in 
lane e  was incubated at 23°C  instead of 4°C  for 90  min with  18 
Ixg/ml ASOR-LPO and then washed as in lane d to remove surface- 
bound conjugate. Numbers at right correspond to molecular mass 
in kilodaltons. 
Y-2448) was the generous gift of Dr. Morey Slodki, U. S. Department of 
Agriculture, Northern Regional Laboratory, Peoria, IL. Dictyostelium dis- 
coideum  cultures  were  provided  by  Dr.  Catherine  Berlot,  Stanford 
University. 
Cell Culture 
HepG2 cells were grown and maintained as described by Schwartz et al. 
(32). Cells were harvested by passage through a 25-gauge needle after tryp- 
sinization to obtain uniform monolayers. 5E9 clone 11 cells (American Type 
Culture  Collection, Rockville,  MD)  were grown as an ascites tumor in 
BALB/c mice. 
Antibodies 
Monoclonal transferrin receptor antibodies were purified from 5E9 clone 
11  cell ascites fluid by  DEAE-Affigel Blue (BioRad Laboratories,  Rich- 
mond,  CA)  chromatography (5).  Antibodies to the Man-6-P receptor  c~ 
were generously provided by Yukiko Goda of  this laboratory, and were pre- 
pared using Man-6-P receptor  °  purified to homogeneity from a detergent- 
solubilized, bovine liver total microsome fraction (9) by chromatography on 
a column ofD. discoideum lysosomal enzymes linked to Afligel-10 (BioRad 
Laboratories)  as described (18). The receptor was eluted with 2 mM Man-6-P 
in a  buffer containing 0.5%  3-[(3-cholamidopropyi)dimethylammonio]-l- 
propanesulfonate instead of Triton X-100 to facilitate detergent removal by 
dialysis before immunization. 
Preparation of  Conjugate 
Asialoorosomucoid (ASOR) coupled to lactoperoxidase (ASOR-LPO) was 
prepared exactly as described by Watts (39). The product corresponding to 
one  molecule of LPO  conjugated to one  or two  molecules ASOR  was 
purified by chromatography on a 250-ml Sephacryl S-300 column run at 16 
rnl/h. The conjugate retained >95% of its original LPO activity, measured 
by the procedure of Hubbard and Cohn (19). 
Endosome Labeling 
The procedure of  Watts (39) was employed using 10-cm dishes per reaction. 
Monolayers were incubated with conjugate for 2 h in a 23°C waterbath to 
"load" endosomes; iodinations were carried out at 4°C for 2  h.  Culture 
dishes were placed onto ice-cooled steel blocks covered with water-soaked 
paper towels to maintain an iodination reaction temperature of ~4°C. After 
terminating the reaction, cells were harvested directly into  1 ml, 0.15 M 
NaCI, 20 mM Na phosphate, 1% Triton X-100, 0.1% deoxycholate (buffer 
A) plus 5 mM KI, and frozen in liquid nitrogen for subsequent analyses. 
AJfinity Chromatography 
Pentamannosyl-6-phosphate fragments of yeast phosphomannan were pre- 
pared according to Murray  and Neville (27),  and were derivatized with 
p-(aminophenyl)ethylamine (Aldrich Chemical Co., Milwaukee, WI) and 
coupled to cyanogen bromide activated Sepbarose CL-4B (Sigma Chemical 
Co.) as described (3).  Labeled extracts (0.4 ml) were chromatographed at 
4°C on 0.5-ml columns in 50 mM imidazole, pH 7,  150 mM NaCI, 5 mM 
13-glycerophosphate,  0.05 %  Triton  X-100 according to  the procedure of 
Hoflack and Kornfeld (18). 
Metabolic Labeling 
Cell monolayers were rinsed once in PBS and then incubated for 16-18 h 
with 135S]methionine (0.1 mCi/mi) in methionine-free medium containing 
10% dialyzed fetal calf serum and supplemented with 5 IxM methionine. At 
the end of the labeling period, the radioactive medium was replaced with 
complete alpha-MEM containing 10%  fetal calf serum. 
Other Techniques 
Inununoprecipitations were carried out as described (22) except that Staphy- 
lococcus aureus cells were substituted for protein A-Sepharose. Protein was 
determined by the method of  Lowry et al. (23) or Bradford (1) using BioRad 
reagent and bovine serum albumin as standard. Polyacrylamide gel electro- 
phoresis was carried out by the method of Laernmli (21) using myosin (205 
kD), bovine brain clathrin (180, 36, 33 kD), phosphorylase B (94 kD), bo- 
vine serum albumin (68 kD), tubulin (55 kD), ovalbumin (43.5  kD), and 
alcohol dehydrogenase (37 kD) as standards. Densitometry was carried out 
using a Quick Scan JR (Helena Laboratories, Beaumont, TX) scanning den- 
sitometer. Care was taken to ensure linearity of the response. 
To determine the fraction of Man-6-P receptor that had contacted ex- 
tracellularly  administered antibody,  cell  monolayers  were  labeled  with 
[35S]methionine  and then incubated with antisera for various times. Ceils 
were then washed three times with PBS, harvested by addition of 1 mi of 
buffer A, and centrifuged at 150,000 g for 5 min. Samples were then split 
into two portions: one portion was incubated directly with fixed S.  aureus 
cells plus 2 gl of preimmune serum; the other portion was incuba~l with 
an additional 2 Ixl of  anti-Man-6-P receptor serum for 2 h at 20°C, followed 
by  S.  aureus  cells.  Samples  were  then  handled  as  described  for  im- 
munoprecipitations. 
Results 
Mellman and colleagues have shown that lactoperoxidase in- 
ternalized by fluid-phase endocytosis can be used to label en- 
docytic vesicle proteins selectively from within intact ceils 
(24, 26). By conjugating lactoperoxidase to a specific ligand, 
Watts has adapted this procedure to make use of the advan- 
tages of receptor-mediated endocytosis (39).  Unlike fluid- 
phase uptake, ligands internalized by receptor-mediated en- 
docytosis can be concentrated within cells by virtue of their 
high-affinity association with specific cell surface receptors. 
The receptor-mediated uptake and labeling procedure de- 
scribed by "~atts (39) was employed to iodinate proteins with- 
in the endosome compartment of human hepatoma (HepG2) 
cells. Cells were incubated with a conjugate of asialooroso- 
mucoid coupled to lactoperoxidase (ASOR-LPO). As shown 
previously (39),  the conjugate bound to cell surface asialo- 
glycoprotein receptors, because after binding at 4°C, ASOR- 
LPO could catalyze a cell surface iodination reaction in the 
presence of I~I, glucose oxidase, and glucose (Fig. 1 a) that 
depended entirely upon the presence of the conjugate (Fig. 
1 b),  was greatly diminished by addition of excess ASOR 
(Fig.  1 c)  and was eliminated after washing the cells with 
5 mM  EDTA,  a  treatment that  interferes  with  receptor- 
ligand association (Fig. 1 d). If  cells were allowed to endocy- 
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of endosomal proteins. HepG2 cells were processed for endosome 
labeling as in Fig. 1 e. 1-ml fractions were collected; fractions were 
analyzed on a 6.5% acrylamide gel and a portion of the resulting 
autoradiograph is shown. Lane a, fraction 2; lane b, fraction 5. 
tose ASOR-LPO at 23°C and were then washed with EDTA 
to remove cell-surface conjugate, endosome-specific iodina- 
tion could be achieved after incubating intact cells with ~25I, 
glucose oxidase, and glucose (Fig.  1 e). Under these condi- 
tions, most of the ASOR-LPO is not transported beyond en- 
dosomes to lysosomes (8),  and the 125I and extracellularly 
generated  H202  must  permeate  endosomal  and  plasma 
membranes for intraorganellar iodination (26). Given these 
permeability barriers, it is not unexpected that the level of 
endosomal iodination (Fig.  1 e) is much lower than that ob- 
tained at the cell surface (Fig.  1 a). 
To verify further that the observed labeling was occurring 
intracellularly, an endosome-labeling reaction was carried 
out as before (as in Fig.  1 e), and at the end of the labeling 
period, cells were washed again with EDTA to remove any 
residual ASOR-LPO that might have remained on the cell 
surface.  ASOR-LPO  is  self-iodinated during  the  labeling 
procedure, and can be used to monitor the cellular topogra- 
phy of the reaction (24). Gel electrophoresis and autoradio- 
graphic analysis did not detect any ASOR-LPO in the EDTA 
wash, even after long exposure (data not shown), confirming 
that the labeling reaction occurred within an intracellular 
compartment. 
Watts has shown that the transferrin receptor is among the 
major  polypeptides  labeled  within  endosomes  of HepG2 
cells using this procedure (39).  To determine whether the 
Man-6-P receptor  c~ could also be detected in endosomes, 
HepG2 cells were processed for endosome labeling (as in 
Fig.  1 e), and the resulting extract was subjected to affinity 
chromatography on a pentamannosyl-6-phosphate-Sepharose 
column. The Man-6-P receptor  cI should bind selectively to 
this resin in the absence of divalent cations. As can be seen 
in Fig. 2 A, a peak of radioactive material was eluted from 
this column after addition of Man-6-P but not glucose-6-P, 
characteristic of this receptor. Analysis of the fractions by 
SDS-PAGE and autoradiography confirmed that the eluted 
material corresponded to the 215-kD Man-6-P receptor (Fig. 
2 B). Therefore, the endosome-radiolabeling protocol led to 
iodination of the Man-6-P receptor  °  in HepG2 cell endo- 
somes. 
If the 215-kD Man-6-P receptor accumulates in the Golgi 
apparatus in the absence of lysosomal hydrolase synthesis, 
it should be correspondingly depleted from endosomes after 
Figure 3. Effect of  cycloheximide  on endosomal Man-6-P and trans- 
ferrin receptors. Individual plates of HepG2 cells were pretreated 
for the  indicated times with  100 I.tg/ml cycloheximide and then 
processed for endosomal protein iodination as in Fig. 1 e. (a) Im- 
munoprecipitation of Man-6-P  receptorO; (b)  immunoprecipita- 
tion of  transferrin receptor. The plate samples used for immunopre- 
cipitation  in a  are  identical with those  used  in b.  Plate 9  was 
incubated with ASOR-LPO in the absence of cycloheximide; all 
other ASOR-LPO incubations were carried out in the continued 
presence of cycloheximide. 
a period of cycloheximide treatment. To test this, cells were 
treated with cycloheximide (100 gg/ml) for up to 6 h to permit 
complete transit of newly synthesized lysosomal hydrolases 
to lysosomes. A variety of hydrolases require only 1-3 h for 
complete lysosome delivery (10, 12, 33). The conditions em- 
ployed blocked at least 98 % of  protein synthesis as measured 
by [35S]methionine  incorporation, and did not affect Man- 
6-P receptor turnover (data not shown). 
Cells treated with cycloheximide  for various times were in- 
cubated with ASOR-LPO for 2 h at 23  °, washed with EDTA 
to remove surface-bound conjugate, and then processed as 
before for endosomal radiolabeling. Individual samples were 
then analyzed for both the Man-6-P receptor  °  (Fig.  3  a) 
and the transferrin receptor (Fig. 3 b). The level of the trans- 
ferrin receptor in endosomes should not be affected by cyclo- 
heximide treatment in that this protein has been shown to cycle 
through the endocytic pathway at the same rate in the pres- 
ence or absence of  bound transferrin (40), and cycloheximide 
has no effect on the recycling of this receptor in the same cell 
line under virtually identical conditions (6). Therefore, the 
transferrin receptor serves as an internal standard for endo- 
somal labeling. 
The ratio of labeled Man-6-P receptor to transferrin recep- 
tor was found to be constant (compare Fig. 3 a with b). The 
observed differences between plates  were due  entirely to 
differences in cell number, as shown by protein determina- 
tion; the radioactive incorporation per milligram protein was 
comparable for all samples (data not shown). Quantitation of 
the  data presented in  Fig.  3  showed that  the relative en- 
dosomal concentrations of the Man-6-P receptor  cx and the 
transferrin receptor were unaffected by cycloheximide treat- 
ment (Fig. 4). 
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Figure 4. Quantitation of the effect of cycloheximide on endosomal 
Man-6-P and transferrin receptors. Data presented in Fig. 3, a and 
b were quantitated by densitometric scanning. The relative amounts 
of the two labeled receptors in a single sample after various times 
of treatment are shown in arbitrary units; triangles represent the av- 
erage of duplicate samples. 
To determine whether the endosome labeling procedure 
would have been able to detect a decrease in the level of Man- 
6-P receptors, we sought alternative conditions under which 
the level of endosomal Man-6-P receptors would be decreased. 
Mellman and colleagues have demonstrated that the Fc re- 
ceptor can be directed to lysosomes when cross-linked by 
bound antibodies (25). von Figura and co-workers have ob- 
tained  similar results  for the  Man-6-P receptor,  and  have 
shown that fibroblasts can be virtually depleted of the Man- 
6-P receptor after antibody treatment (13, 36). As shown in 
Fig.  5, antibodies can also be used to deplete HepG2 cells 
of a  large  fraction of their total complement of Man-6-P 
receptors.  When compared with cells treated with preim- 
mune serum and goat anti-rabbit IgG (Fig. 5, left),  HepG2 
cells treated with  anti-Man-6-P  receptor  serum contained 
33% less receptor after a 5-h incubation; only one-third of 
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Figure  5.  Antibody-mediated depletion of total cellular  Man-6-P 
receptors.  [35S]methionine-labeled HepG2 cell  monolayers were 
treated with either 10% preimmune  serum followed by 50 Itg/ml 
goat anti-rabbit IgG (left), 10% anti-Man-6-P receptor serum fol- 
lowed by preimmune serum (center), or 10% anti-Man-6-P recep- 
tor serum followed by 50 Ixg/ml goat anti-rabbit IgG (right). Pri- 
mary antibody incubations were for 5 h; plates were then washed 
three times with PBS, and incubated for 3 h with the second anti- 
body. Monolayers were then washed, harvested,  and analyzed for 
total cellular  [35S]transferrin re,  ceptors (hatched bars) or total cel- 
lular [35S]Man-6-P receptors (solid bars) by immunoprecipitation, 
gel electrophoresis,  autoradiography, and densitometry. 
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Figure  6.  Effect of anti-Man-6-P receptor antibody treatment on 
the level of endosomal Man-6-P receptors. HepG2 cell monolayers 
were  treated  with  either  preimmune  serum  followed by  goat 
anti-rabbit IgG (left) or anti-Man-6-P receptor serum followed by 
goat anti-rabbit IgG (right) as described in Fig. 5. Endosomal pro- 
teins were then radiolabeled with t2sI (as in Fig. 3) and analyzed 
by immunoprecipitation, gel electrophoresis, autoradiography, and 
densitometry.  12sI-transferrin receptor  is shown in hatched bars; 
uSI-Man-6-P receptor  is  shown  in  solid  bars.  The  fraction  of 
receptor  detected  after  receptor  antibody  treatment  (right)  is 
presented  relative to the control sample (left). 
the total receptor remained in these cells if a cross-linking 
second antibody was also employed. Treatment of cells with 
anti-Man-6-P receptor serum had no effect on the level of to- 
tal cellular transferrin receptors (Fig. 5). The observed rate 
of antibody-induced, total receptor loss in HepG2 cells was 
very similar to that measured for fibroblasts (13). 
To  investigate  the  sensitivity  of the  endosome-labeling 
procedure, antibody treatment was used to deplete cells of 
a large fraction of their total cellular Man-6-P receptors, and 
the level of Man-6-P receptors remaining in endosomes was 
then determined. Under conditions that deplete cells of two- 
thirds of their Man-6-P receptors (Fig. 5), the level of Man- 
6-P receptors detected by the endosome-radiolabeling pro- 
cedure also decreased by two-thirds,  whereas the level of 
transferrin receptors was unchanged (Fig.  6).  This experi- 
ment demonstrates that the endosome-specific radiolabeling 
procedure can detect a change in endosomal receptor con- 
tent.  Furthermore, the correspondence between the loss of 
total cellular Man-6-P receptors (66%) and the loss of en- 
dosomal Man-6-P receptors (67 %) indicates that the pool of 
Man-6-P receptors labeled in this experiment was in equilib- 
rium with the total cellular Man-6-P receptor pool. 
The  experiments  described  above demonstrate  that  the 
level of Man-6-P receptors present in endosomes does not 
change in the absence of new ligand synthesis. These find- 
ings are consistent with the notion that the Man-6-P receptor 
cycles continuously between cellular compartments, whether 
or not it is occupied.  This conclusion would only be valid 
if the receptor remained in equilibrium with other cellular 
compartments in the absence of ligand synthesis. The ability 
of intracellular Man-6-P receptors to contact extracellular 
antibodies was used as a measure of the cycling of this recep- 
tor between cellular compartments. In this type of experi- 
ment,  antibodies  are used to  mark the  appearance of the 
receptor at the cell surface (or in endosomes), rather than to 
stimulate receptor degradation. 
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Figure 7. Effect of cycloheximide on the cycling of Man-6-P recep- 
tors to the cell surface and endosomes. Lanes 1 and 2, [3SS]meth- 
ionine-labeled Chinese hamster ovary cells were trealr.xt for either 
0 or 180 min in the presence of 10% anti-Man-6-P receptor serum. 
Cells were then washed, harvested, and analyzed for the fraction 
of total cellular Man-6-P receptors that had contacted antibody. 
Lanes  3  and  4,  [35S]methionine-labeled HepG2  cells  were  in- 
cubated for 3 h in the presence or absence of 100 ~tg/ml cyclohexi- 
mide, washed three times in PBS, and then incubated for an addi- 
tional  180 min  with  10%  anti-Man-6-P  receptor  serum  in  the 
continued presence or absence of cycloheximide. The fraction of 
the total Man-6-P receptor that had contacted receptor antibody was 
then determined. 
As  shown previously (29),  virtually all of the Man-6-P 
receptors in Chinese hamster ovary (CHO) cells contact ex- 
tracellular antibody within 180 min (Fig. 7). The process is 
somewhat slower in HepG2 cells: only 42% of the Man-6-P 
receptor contacted extracellular antibody in an equivalent 
time period. Most importantly, the same amount of receptor 
(44 %) contacted extracellular antibodies in cells treated with 
cycloheximide.  Garttmg  et al.  (13) have obtained  similar 
results using human fibroblasts. Therefore, the equilibrium 
of the Man-6-P receptor between cellular compartments ap- 
pears to be unchanged in the absence of protein synthesis. 
Discussion 
Immunocytochemical experiments indicated that the Man-6-P 
receptor  c~ accumulates in the Golgi apparatus under condi- 
tions in which synthesis of lysosomal hydrolases or the Man- 
6-P recognition marker is blocked (2, 4, but see also  15). 
This would require that the departure of the Man-6-P recep- 
tor from the Golgi apparatus be coupled to ligand binding. 
In an attempt to confirm these observations using biochemi- 
cal methods, we have used an endosome-specific labeling 
procedure to detect and quantify the Man-6-P receptor  cI as 
well as the transferrin receptor in HepG2 cell endosomes. If 
the Man-6-P receptor accumulates in the Golgi complex, it 
should  be  concomitantly  depleted  from  endosomes,  be- 
cause the  receptor is  in  equilibrium between  these com- 
partments.  Under conditions in which 98 % of protein syn- 
thesis was blocked, and after incubation periods that should 
have been far beyond what was necessary to transfer most 
newly synthesized lysosomal hydrotases to lysosomes (10, 
12, 33), we were unable to detect any alteration in the steady- 
state levels of either the Man-6-P or the transferrin receptor 
within endosomes. Analogous results were obtained using 
tunicamycin to block N-linked oligosaccharide addition and 
thus attachment of the Man-6-P recognition marker (data 
not shown). 
Our inability to detect a change in the level of these recep- 
tors was  not due to a  lack of sensitivity of our detection 
method, because a decrease in endosomal Man-6-P recep- 
tors  was  observed in cells depleted of these receptors by 
cross-linking antibody treatment. Furthermore, the receptor- 
depletion experiments demonstrated that the pool of recep- 
tors labeled by ASOR-LPO was in equilibrium with total cel- 
lular Man-6-P receptors, in that the decrease in endosomal 
Man-6-P  receptors  paralleled  the  loss  of total  Man-6-P 
receptors within these ceils. We cannot explain the discrep- 
ancy between these biochemical data and the immunocyto- 
chemical experiments of Brown and Farquhar (2, 4). 
Endosomal levels of  both labeled and unlabeled transferrin 
receptors were unchanged in the absence of  protein synthesis 
(this work and Ciechanover et al. [6]). Therefore, the con- 
centration of ASOR-LPO in endosomes must also have re- 
mained  roughly  constant,  in  that  iodination  levels  are 
proportional to ASOR-LPO concentration. Because, at least 
by this criterion, cycloheximide treatment did not signifi- 
cantly alter endosome volume, we can conclude that not only 
the level, but also the actual concentration of the Man-6-P 
receptor remained unchanged. 
The  Man-6-P  receptor transports  lysosomal hydrolases 
from the Golgi complex to a prelysosomal compartment, and 
then returns to the Golgi complex for another round of trans- 
port.  Yet a  small amount of this intracellular receptor can 
also be detected at the cell surface and in peripheral endo- 
somes,  and such endocytic Man-6-P receptors equilibrate 
rapidly with those that are Golgi complex-derived. We do 
not yet know whether the prelysosomal compartment used 
by the Man-6-P receptor to unload lysosomal enzymes is in 
fact an endosome compartment shared with the endocytic 
pathway, or whether it represents a distinct, low pH compart- 
ment that communicates with late endosomes. The experi- 
ments  described here involved radiolabeling of receptors 
within cellular compartments that had access to endocytosed 
ASOR-LPO after 2  h  at 23°C.  In that this temperature is 
somewhat higher than that originally reported for blockage 
of transport beyond endosomes (8), it is possible that the la- 
beled receptors we studied were present not only in periph- 
eral and late endosomes, but also in more distal compart- 
ments that might include a potentially distinct, prelysosome 
compartment. Further experiments will be needed to deter- 
mine the precise localization of the radiolabeled Man-6-P 
receptors. 
The steady-state measurements reported here indicate that 
the  cellular  distribution  of the  Man-6-P  receptor  is  not 
affected by the presence or absence of transiting lysosomal 
enzymes. Furthermore, Man-6-P receptors in the Golgi ap- 
paratus, endosomes, and at the cell surface are in rapid equi- 
librium (29,  36),  even in the absence of protein synthesis 
(this work and Gartung et al.  [13]).  Taken together, these 
findings strongly suggest that the Man-6-P receptor cycles 
continuously between intracellular compartments, with or 
without bound ligand. A major challenge for the future will 
be to identify the signals used to target Man-6-P receptors 
in the Golgi apparatus to a prelysosomal compartment, and 
then return them to the Golgi complex for another round of 
lysosomal hydrolase transport. 
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Note Added in Proof: Concurrent with the submittal of this article for publi- 
cation, other authors reported in this journal that unoccupied endosomal 
Man-6-P receptors recycle rapidly to the Golgi complex (Brown,  W.  J., 
J.  Goodhouse, and M.  G.  Farquhar,  1986, £  Cell Biol.  103:1235-1247). 
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